120 related articles for article (PubMed ID: 15128982)
1. Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment.
Suh RD; Goldin JG; Wallace AB; Sheehan RE; Heinze SB; Gitlitz BJ; Figlin RA
Radiology; 2004 May; 231(2):359-64. PubMed ID: 15128982
[TBL] [Abstract][Full Text] [Related]
2. Technical Feasibility and Safety of Repeated Computed Tomography-Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC.
Shahrouki P; Lee JM; Barclay J; Khan SN; Genshaft S; Abtin F; Dubinett SM; Lisberg A; Sharma S; Garon EB; Suh R
JTO Clin Res Rep; 2021 Nov; 2(11):100242. PubMed ID: 34806054
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
5. Human gene therapy for melanoma: CT-guided interstitial injection.
Waddill W; Wright W; Unger E; Stopeck A; Akporiaye E; Harris D; Grogan T; Schluter S; Hersh E; Stahl S
AJR Am J Roentgenol; 1997 Jul; 169(1):63-7. PubMed ID: 9207502
[TBL] [Abstract][Full Text] [Related]
6. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
Galanis E; Hersh EM; Stopeck AT; Gonzalez R; Burch P; Spier C; Akporiaye ET; Rinehart JJ; Edmonson J; Sobol RE; Forscher C; Sondak VK; Lewis BD; Unger EC; O'Driscoll M; Selk L; Rubin J
J Clin Oncol; 1999 Oct; 17(10):3313-23. PubMed ID: 10506635
[TBL] [Abstract][Full Text] [Related]
8. Fine-needle percutaneous biopsy of renal masses with helical CT guidance.
Lechevallier E; André M; Barriol D; Daniel L; Eghazarian C; De Fromont M; Rossi D; Coulange C
Radiology; 2000 Aug; 216(2):506-10. PubMed ID: 10924578
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
Saffran DC; Horton HM; Yankauckas MA; Anderson D; Barnhart KM; Abai AM; Hobart P; Manthorpe M; Norman JA; Parker SE
Cancer Gene Ther; 1998; 5(5):321-30. PubMed ID: 9824052
[TBL] [Abstract][Full Text] [Related]
10. Radiofrequency ablation combined with renal arterial embolization for the treatment of unresectable renal cell carcinoma larger than 3.5 cm: initial experience.
Yamakado K; Nakatsuka A; Kobayashi S; Akeboshi M; Takaki H; Kariya Z; Kinbara H; Arima K; Yanagawa M; Hori Y; Kato H; Sugimura Y; Takeda K
Cardiovasc Intervent Radiol; 2006; 29(3):389-94. PubMed ID: 16502180
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex.
Daniels GA; Galanis E
Curr Opin Mol Ther; 2001 Feb; 3(1):70-6. PubMed ID: 11249734
[TBL] [Abstract][Full Text] [Related]
12. Sequential combination treatment (arterial embolization and percutaneous radiofrequency ablation) of inoperable renal cell carcinoma: single-center pilot study.
Nakasone Y; Kawanaka K; Ikeda O; Tamura Y; Yamashita Y
Acta Radiol; 2012 May; 53(4):410-4. PubMed ID: 22393159
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial.
Mahvi DM; Henry MB; Albertini MR; Weber S; Meredith K; Schalch H; Rakhmilevich A; Hank J; Sondel P
Cancer Gene Ther; 2007 Aug; 14(8):717-23. PubMed ID: 17557109
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.
Wagner JR; Walther MM; Linehan WM; White DE; Rosenberg SA; Yang JC
J Urol; 1999 Jul; 162(1):43-5. PubMed ID: 10379736
[TBL] [Abstract][Full Text] [Related]
15. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Amato RJ; Morgan M; Rawat A
Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
Escudier B; Choueiri TK; Oudard S; Szczylik C; Négrier S; Ravaud A; Chevreau C; Venner P; Champagne P; Croteau D; Dupont E; Hariton C; Bukowski RM
J Urol; 2007 Nov; 178(5):1901-5. PubMed ID: 17868728
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous cryoablation of anterior renal masses: technique, efficacy, and safety.
Schmit GD; Atwell TD; Leibovich BC; Callstrom MR; Kurup AN; Woodrum DA; Charboneau JW
AJR Am J Roentgenol; 2010 Dec; 195(6):1418-22. PubMed ID: 21098204
[TBL] [Abstract][Full Text] [Related]
19. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
